Hatten wir auch noch nicht, heute gabs Quartalszahlen, wurden wieder mit 13% belohnt.
Wo wollen die den mal hin, falls mal ein Gewinn pro Share erzielt wird?
Gruss E.
chart.bigcharts.com/bc3/quickchart/...05&mocktick=1&rand=9483"
Columbia Laboratories Reports First Quarter 2003 Results
TUESDAY, MAY 13, 2003 5:35 PM
- BusinessWire
LIVINGSTON, N.J., May 13, 2003 (BUSINESS WIRE) -- Columbia Laboratories (COB) today reported a loss for the first quarter ended March 31, 2003 of $4,704,070, or $0.13 per share, on sales of $3,605,546.
This compares to a loss of $3,380,943, or $0.10 per share, on sales of $576,811 in the comparable 2002 period, and a loss of $6,734,160 or $0.19 per share, on sales of $2,346,055 in the fourth quarter of 2002.
First quarter 2003 net revenues reflect increasing sales of Crinone(R) 8% (progesterone gel) to Serono, sales of Prochieve(TM) 8% (progesterone gel), Rephresh(TM) Vaginal Gel and Advantage-S(R) Bioadhesive Contraceptive Gel as well as initial distribution of Prochieve(TM) 4% (progesterone gel) to a few key customers in late March. First quarter 2003 selling and distribution expenses reflect the Company's commercialization activities, which began in the third quarter of 2002.
Fred Wilkinson, Columbia's president and chief executive officer said, "Sales of our women's healthcare products continued to increase during the first quarter of 2003, with total revenues increasing 53.7% over the fourth quarter of 2002 while cost of sales increased only 15.0%. We were particularly pleased with the response by the OB/GYNs to our sales force's efforts and promotional messages, and we are seeing a growing acceptance of those products in the marketplace."
Mr. Wilkinson added, "During the quarter we reached an agreement with Quintiles Transnational Corp. that will help us to commercialize our Striant(TM) testosterone buccal bioadhesive product. Striant is currently under review by FDA with a goal date for agency action of June 19, 2003. Under the terms of this agreement, Quintiles' commercialization unit, Innovex, will provide a dedicated team of approximately 75 sales representatives for two-and-a-half years on a fee-for-service basis. Additionally, Quintiles' strategic investment group, PharmaBio Development, will pay Columbia $15 million over 5 quarters; the first installment of $3 million was received during the first quarter of 2003. In return, Quintiles will receive a royalty on net sales of Striant in the United States for a seven-year term. Royalty payments will commence with the launch of Striant, and are subject to minimum and maximum amounts. Columbia will be responsible for product distribution, regulatory and medical affairs, marketing, and manufacturing. We are pleased to have expanded our relationship with Quintiles to encompass this exciting product."
Mr. Wilkinson concluded, "Since the close of the quarter, we launched our fourth women's healthcare product, Prochieve 4%, which our sales force is now marketing alongside Prochieve 8%, RepHresh and Advantage-S to our target market of U.S. OB/GYNs. We believe that the addition of Prochieve 4% enables us to continue to effectively leverage our sales force, leading to future potential growth in revenue."
Columbia Laboratories, Inc. is an international pharmaceutical company dedicated to development and commercialization of women's health care and endocrinology products, including those intended to treat infertility, dysmenorrhea, endometriosis and hormonal deficiencies. Columbia is also developing hormonal products for men and a buccal delivery system for peptides. Columbia's products primarily utilize the company's patented Bioadhesive Delivery System (BDS) technology. For more information, please visit www.columbialabs.com.
This press release contains statements that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Those statements include statements regarding the intent, belief or current expectations of the company and its management team. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those projected in the forward-looking statements. Such risks and uncertainties include, among other things, the successful launch and marketing of Prochieve 8% and 4%, RepHresh Vaginal Gel and Advantage-S, timely and successful development of new products, timely and successful completion of clinical studies, success in obtaining acceptance and approval of new products by the FDA and international regulatory agencies, including Striant (testosterone buccal bioadhesive product), and competitive economic and regulatory factors in the pharmaceutical and healthcare industry, general economic conditions and other risks and uncertainties that may be detailed, from time-to-time, in Columbia's reports filed with the Securities and Exchange Commission.
COLUMBIA LABORATORIES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
Wo wollen die den mal hin, falls mal ein Gewinn pro Share erzielt wird?
Gruss E.
Columbia Laboratories Reports First Quarter 2003 Results
TUESDAY, MAY 13, 2003 5:35 PM
- BusinessWire
LIVINGSTON, N.J., May 13, 2003 (BUSINESS WIRE) -- Columbia Laboratories (COB) today reported a loss for the first quarter ended March 31, 2003 of $4,704,070, or $0.13 per share, on sales of $3,605,546.
This compares to a loss of $3,380,943, or $0.10 per share, on sales of $576,811 in the comparable 2002 period, and a loss of $6,734,160 or $0.19 per share, on sales of $2,346,055 in the fourth quarter of 2002.
First quarter 2003 net revenues reflect increasing sales of Crinone(R) 8% (progesterone gel) to Serono, sales of Prochieve(TM) 8% (progesterone gel), Rephresh(TM) Vaginal Gel and Advantage-S(R) Bioadhesive Contraceptive Gel as well as initial distribution of Prochieve(TM) 4% (progesterone gel) to a few key customers in late March. First quarter 2003 selling and distribution expenses reflect the Company's commercialization activities, which began in the third quarter of 2002.
Fred Wilkinson, Columbia's president and chief executive officer said, "Sales of our women's healthcare products continued to increase during the first quarter of 2003, with total revenues increasing 53.7% over the fourth quarter of 2002 while cost of sales increased only 15.0%. We were particularly pleased with the response by the OB/GYNs to our sales force's efforts and promotional messages, and we are seeing a growing acceptance of those products in the marketplace."
Mr. Wilkinson added, "During the quarter we reached an agreement with Quintiles Transnational Corp. that will help us to commercialize our Striant(TM) testosterone buccal bioadhesive product. Striant is currently under review by FDA with a goal date for agency action of June 19, 2003. Under the terms of this agreement, Quintiles' commercialization unit, Innovex, will provide a dedicated team of approximately 75 sales representatives for two-and-a-half years on a fee-for-service basis. Additionally, Quintiles' strategic investment group, PharmaBio Development, will pay Columbia $15 million over 5 quarters; the first installment of $3 million was received during the first quarter of 2003. In return, Quintiles will receive a royalty on net sales of Striant in the United States for a seven-year term. Royalty payments will commence with the launch of Striant, and are subject to minimum and maximum amounts. Columbia will be responsible for product distribution, regulatory and medical affairs, marketing, and manufacturing. We are pleased to have expanded our relationship with Quintiles to encompass this exciting product."
Mr. Wilkinson concluded, "Since the close of the quarter, we launched our fourth women's healthcare product, Prochieve 4%, which our sales force is now marketing alongside Prochieve 8%, RepHresh and Advantage-S to our target market of U.S. OB/GYNs. We believe that the addition of Prochieve 4% enables us to continue to effectively leverage our sales force, leading to future potential growth in revenue."
Columbia Laboratories, Inc. is an international pharmaceutical company dedicated to development and commercialization of women's health care and endocrinology products, including those intended to treat infertility, dysmenorrhea, endometriosis and hormonal deficiencies. Columbia is also developing hormonal products for men and a buccal delivery system for peptides. Columbia's products primarily utilize the company's patented Bioadhesive Delivery System (BDS) technology. For more information, please visit www.columbialabs.com.
This press release contains statements that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Those statements include statements regarding the intent, belief or current expectations of the company and its management team. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those projected in the forward-looking statements. Such risks and uncertainties include, among other things, the successful launch and marketing of Prochieve 8% and 4%, RepHresh Vaginal Gel and Advantage-S, timely and successful development of new products, timely and successful completion of clinical studies, success in obtaining acceptance and approval of new products by the FDA and international regulatory agencies, including Striant (testosterone buccal bioadhesive product), and competitive economic and regulatory factors in the pharmaceutical and healthcare industry, general economic conditions and other risks and uncertainties that may be detailed, from time-to-time, in Columbia's reports filed with the Securities and Exchange Commission.
COLUMBIA LABORATORIES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
